6 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe https://www.zacks.com/stock/news/2250719/amarin-amrn-up-7-on-intellectual-property-wins-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250719 Apr 04, 2024 - Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/02/29/amarin-plc-amrn-q4-2023-earnings-call-transcript/?source=iedfolrf0000001 Feb 29, 2024 - AMRN earnings call for the period ending December 31, 2023.
Can Low Occupancy Rate Affect Select Medical (SEM) Q4 Earnings? https://www.zacks.com/stock/news/2228685/can-low-occupancy-rate-affect-select-medical-sem-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2228685 Feb 20, 2024 - Select Medical's (SEM) fourth-quarter results are likely to reflect growing visits in Outpatient Rehabilitation and Concentra.
Are Medical Stocks Lagging Amarin (AMRN) This Year? https://www.zacks.com/stock/news/2209522/are-medical-stocks-lagging-amarin-amrn-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2209522 Jan 12, 2024 - Here is how Amarin (AMRN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript) https://seekingalpha.com/article/4662245-amarin-corporation-plc-amrn-ceo-pat-holt-presents-42nd-annual-j-p-morgan-healthcare?source=feed_sector_transcripts Jan 10, 2024 - Amarin Corporation plc (NASDAQ:NASDAQ:AMRN) 42nd Annual J.P.
What Makes Amarin (AMRN) a New Buy Stock https://www.zacks.com/stock/news/2193741/what-makes-amarin-amrn-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2193741 Dec 05, 2023 - Amarin (AMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pages: 1

Page 1